blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

Latvia joins the Federated Register
Click here for more information on the Federated Register.

2025-04-16

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3421039

EP3421039 - DRUG FOR CANCER THERAPY CHARACTERIZED BY ADMINISTERING COMBINATION BETWEEN AXL INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  12.08.2022
Database last updated on 26.04.2025
FormerThe patent has been granted
Status updated on  03.09.2021
FormerGrant of patent is intended
Status updated on  27.04.2021
FormerExamination is in progress
Status updated on  21.08.2020
FormerGrant of patent is intended
Status updated on  15.04.2020
FormerExamination is in progress
Status updated on  09.10.2019
FormerRequest for examination was made
Status updated on  30.11.2018
FormerThe international publication has been made
Status updated on  01.09.2017
Most recent event   Tooltip27.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 30.10.2024  [2024/44]
Applicant(s)For all designated states
ONO Pharmaceutical Co., Ltd.
1-5, Doshomachi 2-chome Chuo-ku
Osaka-shi, Osaka 541-8526 / JP
[2019/01]
Inventor(s)01 / TANAKA, Kohei
c/o ONO PHARMACEUTICAL CO. LTD.
1-1 Sakurai 3-chome
Shimamoto-cho
Mishima-gun Osaka 618-8585 / JP
02 / YASUHIRO, Tomoko
c/o ONO PHARMACEUTICAL CO. LTD.
1-1 Sakurai 3-chome
Shimamoto-cho
Mishima-gun Osaka 618-8585 / JP
 [2019/01]
Representative(s)Grünecker Patent- und Rechtsanwälte PartG mbB
Leopoldstraße 4
80802 München / DE
[2019/01]
Application number, filing date17756670.024.02.2017
[2019/01]
WO2017JP07219
Priority number, dateJP2016003520626.02.2016         Original published format: JP 2016035206
[2019/01]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017146236
Date:31.08.2017
Language:JA
[2017/35]
Type: A1 Application with search report 
No.:EP3421039
Date:02.01.2019
Language:EN
[2019/01]
Type: B1 Patent specification 
No.:EP3421039
Date:06.10.2021
Language:EN
[2021/40]
Search report(s)International search report - published on:JP31.08.2017
(Supplementary) European search report - dispatched on:EP08.11.2018
ClassificationIPC:A61K31/4709, A61K39/395, A61K45/00, A61P35/00, A61P43/00, C07K16/18
[2019/01]
CPC:
A61K31/4709 (EP,US); A61K31/519 (EP,US); A61K39/395 (EP,US);
A61K45/00 (EP,US); A61P35/00 (EP,US); C07K16/18 (EP,US);
C07K16/2827 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/01]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:MEDIKAMENT ZUR BEHANDLUNG VON KREBS DURCH VERABREICHUNG EINER KOMBINATION AUS EINEM AXL-HEMMER UND IMMUN-CHECKPOINT-INHIBITOR[2019/01]
English:DRUG FOR CANCER THERAPY CHARACTERIZED BY ADMINISTERING COMBINATION BETWEEN AXL INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR[2019/01]
French:MÉDICAMENT POUR LE TRAITEMENT DU CANCER CARACTÉRISÉ PAR L'ADMINISTRATION D'UNE ASSOCIATION D'UN INHIBITEUR DE L'AXL ET D'UN INHIBITEUR DE POINT DE CONTRÔLE IMMUNITAIRE[2019/01]
Entry into regional phase21.08.2018Translation filed 
21.08.2018National basic fee paid 
21.08.2018Search fee paid 
21.08.2018Designation fee(s) paid 
21.08.2018Examination fee paid 
Examination proceduredeletedDate on which the examining division has become responsible
21.08.2018Examination requested  [2019/01]
20.05.2019Amendment by applicant (claims and/or description)
14.10.2019Despatch of a communication from the examining division (Time limit: M02)
26.11.2019Reply to a communication from the examining division
16.04.2020Communication of intention to grant the patent
19.08.2020Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
28.04.2021Communication of intention to grant the patent
26.08.2021Fee for grant paid
26.08.2021Fee for publishing/printing paid
26.08.2021Receipt of the translation of the claim(s)
Opposition(s)07.07.2022No opposition filed within time limit [2022/37]
Fees paidRenewal fee
25.02.2019Renewal fee patent year 03
13.02.2020Renewal fee patent year 04
12.02.2021Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU24.02.2017
AL06.10.2021
AT06.10.2021
CY06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
MC06.10.2021
MK06.10.2021
MT06.10.2021
NL06.10.2021
PL06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SI06.10.2021
SK06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
IE24.02.2022
LU24.02.2022
BE28.02.2022
CH28.02.2022
LI28.02.2022
[2024/44]
Former [2024/23]HU24.02.2017
AL06.10.2021
AT06.10.2021
CY06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
MC06.10.2021
MK06.10.2021
NL06.10.2021
PL06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SI06.10.2021
SK06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
IE24.02.2022
LU24.02.2022
BE28.02.2022
CH28.02.2022
LI28.02.2022
Former [2024/20]HU24.02.2017
AL06.10.2021
AT06.10.2021
CY06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
MC06.10.2021
NL06.10.2021
PL06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SI06.10.2021
SK06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
IE24.02.2022
LU24.02.2022
BE28.02.2022
CH28.02.2022
LI28.02.2022
Former [2024/18]HU24.02.2017
AL06.10.2021
AT06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
MC06.10.2021
NL06.10.2021
PL06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SI06.10.2021
SK06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
IE24.02.2022
LU24.02.2022
BE28.02.2022
CH28.02.2022
LI28.02.2022
Former [2023/10]AL06.10.2021
AT06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
MC06.10.2021
NL06.10.2021
PL06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SI06.10.2021
SK06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
IE24.02.2022
LU24.02.2022
BE28.02.2022
CH28.02.2022
LI28.02.2022
Former [2023/09]AL06.10.2021
AT06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
MC06.10.2021
NL06.10.2021
PL06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SI06.10.2021
SK06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
IE24.02.2022
LU24.02.2022
CH28.02.2022
LI28.02.2022
Former [2023/01]AL06.10.2021
AT06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
MC06.10.2021
NL06.10.2021
PL06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SI06.10.2021
SK06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
LU24.02.2022
Former [2022/49]AL06.10.2021
AT06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
MC06.10.2021
NL06.10.2021
PL06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SK06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
LU24.02.2022
Former [2022/47]AT06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
MC06.10.2021
NL06.10.2021
PL06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SK06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
LU24.02.2022
Former [2022/44]AT06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
MC06.10.2021
NL06.10.2021
PL06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SK06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
Former [2022/35]AT06.10.2021
CZ06.10.2021
DK06.10.2021
EE06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
NL06.10.2021
PL06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SK06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
Former [2022/34]AT06.10.2021
EE06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
NL06.10.2021
PL06.10.2021
RO06.10.2021
RS06.10.2021
SE06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
Former [2022/33]AT06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
NL06.10.2021
PL06.10.2021
RS06.10.2021
SE06.10.2021
SM06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
Former [2022/25]AT06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
NL06.10.2021
PL06.10.2021
RS06.10.2021
SE06.10.2021
BG06.01.2022
NO06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
Former [2022/24]AT06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
NL06.10.2021
PL06.10.2021
RS06.10.2021
SE06.10.2021
BG06.01.2022
GR07.01.2022
IS06.02.2022
PT07.02.2022
Former [2022/23]AT06.10.2021
FI06.10.2021
HR06.10.2021
LT06.10.2021
LV06.10.2021
PL06.10.2021
RS06.10.2021
BG06.01.2022
PT07.02.2022
Former [2022/22]AT06.10.2021
FI06.10.2021
LT06.10.2021
RS06.10.2021
BG06.01.2022
Former [2022/21]AT06.10.2021
RS06.10.2021
BG06.01.2022
Former [2022/19]BG06.01.2022
Documents cited:Search[XY]WO2015012298  (ONO PHARMACEUTICAL CO [JP]) [X] 1-8 * paragraphs [0093] , [0105]; claim 1 * [Y] 1-8;
 [P]EP3026045  (ONO PHARMACEUTICAL CO [JP]) [P] * paragraphs [0086] , [0098]; claim 1 *;
 [YP]WO2016193680  (BERGENBIO AS [NO], et al) [YP] 1-8* claim 1 *;
 [Y]  - Gausdal, "Abstract B014: BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy | Cancer Immunology Research", Cancer Immunol Res 2016;4(1 Suppl):Abstract nr B014., (20160101), URL: http://cancerimmunolres.aacrjournals.org/content/4/1_Supplement/B014, (20181026), XP055519427 [Y] 1-8 * the whole document *

DOI:   http://dx.doi.org/10.1158/2326-6074.CRICIMTEATIAACR15-B014
 [A]  - P. A. OTT ET AL, "CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients", CLINICAL CANCER RESEARCH, US, (20131001), vol. 19, no. 19, doi:10.1158/1078-0432.CCR-13-0143, ISSN 1078-0432, pages 5300 - 5309, XP055458362 [A] 1-8 * abstract *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-13-0143
International search[Y]WO2015012298  (ONO PHARMACEUTICAL CO [JP]) [Y] 1-9 * , claims; paragraphs [0085], [0090] to [0093], [0140], [0354] to [0355] & US 2016/0168121 A1 claims; paragraphs [0135], [0140] to [0143], [0202] to [0203], [0714] to [0724] & EP 3026045 A1 & CN 105408312 A & KR 10-2016-0033707 A *;
 [Y]  - GRO GAUSDAL et al., "Abstract B014: BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy", Cancer Immunology Research, vol. 4, no. Suppl 1, (20160100), URL: http://cancerimmunolres.aacrjournals.org/content/4/1_Supplement/B014, (20170322), XP055519427 [Y] 1-9 * , Abstract *

DOI:   http://dx.doi.org/10.1158/2326-6074.CRICIMTEATIAACR15-B014
 [Y]  - KUNIKO SUNAMI, "CTLA-4 o Hyoteki to shita Gan Men'eki Ryoho", Japanese Journal of Clinical Medicine (special extra issue) Saishin Gan Yakubutsu Ryohogaku, (20140220), vol. 72, pages 280 - 285 [Y] 1-9 * , Introduction *
 [Y]  - SHIN FOONG NIGLOW et al., "Anti-TIM3 Antibody Promotes T Cell IFN-y-Mediated Antitumor Immunity and Suppresses Established Tumors", Cancer Research, (20110515), vol. 71, no. 10, pages 3540 - 3551, XP055181433 [Y] 1-9 * , Abstract *

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-11-0096
 [Y]  - PASERO CHRISTINE et al., "Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity", Immunology Letters, (20130300), vol. 151, no. 1-2, pages 71 - 75, XP055251710 [Y] 1-9 * , Abstract *

DOI:   http://dx.doi.org/10.1016/j.imlet.2013.01.008
 [AP]  - YOSHIZAWA TOSHIO et al., "Abstract LB-218: Development of Axl/Mer inhibitor , ONO-9330547: preclinical evidence supporting the combination with immunotherapeutics", Cancer Research, vol. 76, no. 14 S, (20160700), URL: http://cancerres.aacrjournals.org/content/76/14_Supplement/LB-218, (20170322), XP055537320 [AP] 1-9 * , Abstract *

DOI:   http://dx.doi.org/10.1158/1538-7445.AM2016-LB-218
by applicantWO2007030680
 WO2007057399
 WO2007070872
 WO2008045978
 WO2008080134
 WO2008083356
 WO2008083353
 WO2008083354
 WO2008083367
 WO2008083357
 WO2008128072
 WO2009007390
 WO2009024825
 WO2009047514
 WO2009053737
 WO2009054864
 WO2009127417
 WO2010005876
 WO2010005879
 WO2010090764
 WO2010128659
 WO2012028332
 WO2012135800
 WO2013074633
 WO2013115280
 WO2013162061
 WO2014091265
 WO2015012298
 WO2016006706
 WO2016097918
 WO2016193680
    - Clinical Science, (20120000), vol. 122, pages 361 - 368
    - Proceedings of the national academy of sciences of the United States of America, (20100000), vol. 107, no. 3, pages 1124 - 1129
    - Blood, (20130000), vol. 121, pages 2064 - 2073
    - Nature Reviews Cancer, (20140000), vol. 14, pages 769 - 785
    - "Development of Medicaments", Molecular Design, Hirokawa Shoten, (19900000), vol. 7, pages 163 - 198
    - Nature Reviews Cancer, vol. 12, pages 252 - 264,2012
    - Cancer Cell, (20150000), vol. 27, pages 450 - 461
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.